Citigroup Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $131

Benzinga Newsdesk www.benzinga.com Negative 50.4%

Neg 50.4% Neu 0% Pos 0%

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $136 to $131.